Orchard Therapeutics PLC (ORTX)

NASDAQ
4.85
-0.18(-3.58%)
After Hours
4.88
+0.03(+0.62%)
- Real-time Data
  • Volume:
    764,063
  • Bid/Ask:
    4.85/4.93
  • Day's Range:
    4.84 - 5.19

ORTX Overview

Prev. Close
5.03
Day's Range
4.84-5.19
Revenue
2.6M
Open
5.07
52 wk Range
3.76-9.08
EPS
-1.32
Volume
764,063
Market Cap
584.66M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
471,037
P/E Ratio
-
Beta
-
1-Year Change
-34.25%
Shares Outstanding
120,549,163
Next Earnings Date
Aug 12, 2021
What is your sentiment on Orchard Therapeutics PLC?
or
Market is currently closed. Voting is open during market hours.

Orchard Therapeutics PLC News

Orchard Therapeutics PLC Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell

Orchard Therapeutics PLC Company Profile

Orchard Therapeutics PLC Company Profile

Employees
224

Orchard Therapeutics plc, formerly Orchard Rx Ltd, is a commercial-stage, fully-integrated biopharmaceutical company. It is engaged in manufacturing and commercialization of gene and cell therapies, position to provide transformative therapies to patients suffering from a range of rare diseases. The Company is focused on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders and hemoglobinopathies. Its portfolio includes Strimvelis, its commercial-stage gammaretroviral-based product for the treatment of ADA-SCID five lentiviral product candidates in clinical-stage development and several other product candidates in preclinical development. It is developing OTL-101 as an autologous ex vivo lentiviral gene therapy to sustainably treat patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID) through a single administration.

Read More
  • What's going on?
    0
    • Any target price?
      0
      • I like the Co. But don't trust its CEO, no transparent at all levels and high dilution possibilities
        0
    • Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that it has executed a securities purchase agreement to raise gross proceeds of $150 Million
      0
      • Orchard Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
        0
        • Orchard Therapeutics Receives EC Approval for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD)
          2
          • Sky is the limit.. Head and shoulders are clear
            0
            • I think ORTX is headed towards record highs after the EMA new approvals. We can easily see it trading at $16 very soon according to couple of sell side research reports.
              0
              • I think its flying to $16 very soon
                0
                • Any hope for this crippled stock?
                  0
                  • Any target price?
                    0
                    • 4.84
                      0
                    • 16$ at dec 2021
                      0
                  • Guys, what time trade start?
                    0
                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.